Literature DB >> 23315201

The importance of histological types for treatment and prognosis in laryngeal cancer.

Alfio Ferlito, Lester D R Thompson, Antonio Cardesa, Douglas R Gnepp, Kenneth O Devaney, Juan P Rodrigo, Jennifer L Hunt, Alessandra Rinaldo, Robert P Takes.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23315201     DOI： 10.1007/s00405-012-2343-6

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN： 0937-4477            Impact factor:   2.503


× No keyword cloud information.
  16 in total

Review 1.  Large cell neuroendocrine carcinoma of the head and neck.

Authors:  Kimihide Kusafuka; Alfio Ferlito; James S Lewis; Julia A Woolgar; Alessandra Rinaldo; Pieter J Slootweg; Douglas R Gnepp; Kenneth O Devaney; William D Travis; Leon Barnes
Journal:  Oral Oncol       Date:  2011-10-22       Impact factor: 5.337

2.  Neuroendocrine carcinomas of the larynx: what do the different histologic types really mean?

Authors:  Kenneth O Devaney; Alfio Ferlito; Alessandra Rinaldo
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-30       Impact factor: 2.503

3.  Verrucous carcinoma of the larynx: a review of 53 patients.

Authors:  L J Orvidas; K D Olsen; J E Lewis; V J Suman
Journal:  Head Neck       Date:  1998-05       Impact factor: 3.147

4.  Alveolar soft-part sarcoma of the head and neck: clinical and imaging features in five cases.

Authors:  Ho Sung Kim; Ho Kyu Lee; Young-Cheol Weon; Hyung-Jin Kim
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

5.  Large cell neuroendocrine carcinoma of the larynx: definition of an entity.

Authors:  James S Lewis; David C Spence; Simon Chiosea; E Leon Barnes; Margaret Brandwein-Gensler; Samir K El-Mofty
Journal:  Head Neck Pathol       Date:  2010-06-30

6.  Alveolar soft part sarcoma of the larynx: a case report of an unusual location with immunohistochemical and ultrastructural analyses.

Authors:  Kimihide Kusafuka; Koji Muramatsu; Tsugumi Yabuzaki; Hiroto Ishiki; Rie Asano; Tomoyuki Kamijo; Yoshiyuki Iida; Mitsuru Ebihara; Testuro Onitsuka; Toru Kameya
Journal:  Head Neck       Date:  2008-09       Impact factor: 3.147

7.  Adenosquamous carcinoma of the head and neck: criteria for diagnosis in a study of 12 cases.

Authors:  L Alos; M Castillo; A Nadal; M Caballero; C Mallofre; A Palacin; A Cardesa
Journal:  Histopathology       Date:  2004-06       Impact factor: 5.087

8.  Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck.

Authors:  William H Westra; Janis M Taube; M L Poeta; Shanaz Begum; David Sidransky; Wayne M Koch
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

9.  NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract.

Authors:  Edward B Stelow; Andrew M Bellizzi; Krishan Taneja; Stacey E Mills; Robin D Legallo; Jeffery L Kutok; Jon C Aster; Christopher A French
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

10.  Papillary squamous cell carcinoma of the head and neck: frequent association with human papillomavirus infection and invasive carcinoma.

Authors:  Vickie Y Jo; Stacey E Mills; Mark H Stoler; Edward B Stelow
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394
View more
  3 in total

Review 1.  Squamous cell carcinoma of the oral cavity and circulating tumour cells.

Authors:  Johannes Wikner; Alexander Gröbe; Klaus Pantel; Sabine Riethdorf
Journal:  World J Clin Oncol       Date:  2014-05-10

Review 2.  Some Considerations on the WHO Histological Classification of Laryngeal Neoplasms.

Authors:  Alfio Ferlito; Kenneth O Devaney; Jennifer L Hunt; Henrik Hellquist
Journal:  Adv Ther       Date:  2019-05-22       Impact factor: 3.845

3.  MicroRNA-107 inhibits proliferation and invasion of laryngeal squamous cell carcinoma cells by targeting CACNA2D1 in vitro.

Authors:  Chaoping Huang; Zhenxiao Wang; Kun Zhang; Yanbo Dong; Aobo Zhang; Cheng Lu; Liangfa Liu
Journal:  Anticancer Drugs       Date:  2020-03       Impact factor: 2.389
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.